THU0200 THE CHOICE OF BDMARD OR TSDMARD AS FIRST LINE THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY
Background: The Tool for Administrative Reimbursement Drug Information Sharing (TARDIS) is an electronic platform combining data collection from all Belgian patients with Rheumatoid Arthritis (RA) on advanced therapy, together with a drug reimbursement request. Therapy choice after initial 2 classical synthetic DMARD failure is left to the treating rheumatologist in Belgium. Objectives: To investigate first-line therapy choices for tumor necrosis factor inhibitor (TNFi) biologic (b) DMARDs, non-TNFi bDMARDs or targeted synthetic (ts) DMARDs via patient characteristics and initial treatment res... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2020 |
Reihe/Periodikum: | Annals of the Rheumatic Diseases ; volume 79, issue Suppl 1, page 322-322 ; ISSN 0003-4967 1468-2060 |
Verlag/Hrsg.: |
BMJ
|
Schlagwörter: | General Biochemistry / Genetics and Molecular Biology / Immunology / Immunology and Allergy / Rheumatology |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26536444 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://dx.doi.org/10.1136/annrheumdis-2020-eular.6192 |